EMPEROR-Preserved

Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved EF

Doente / População Intervenção / Exposição Comparação Desfecho

In 5,988 patients with HFpEF (EF > 40 %), empagliflozin reduced HF hospitalisation or CV death compared with placebo.

5988

Desenho

Double-blind RCT

Desfecho

HF hospitalisation or CV death

Relevância

Resultado13.8 % vs 17.1 % (HR 0.79, 95% CI 0.69–0.90, p<0.001). Driven primarily by HF hosp.

Anker SD, et al. N Engl J Med. 2021;385(16):1451-1461. 10.1056/NEJMoa2107038

Discussão e crítica

First unambiguous pharmacological win in HFpEF. Benefit attenuates at very high EF (> 65 %) in pooled analyses. No mortality reduction.